Back

Comparative effectiveness of anti-inflammatory therapies for atherosclerotic cardiovascular disease: a systematic review and network meta-analysis of 16 randomised trials

29 August 2026 (14:15 - 14:45)
Organised by: Logo
Congress Presentation Part of: Targeting inflammation in cardiovascular diseases and pre-clinical models Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Yashasvi Srivastava

(India)

4 More presentations in this session

Presentation thumbnail
Temporal changes and treatment-associated stabilization of aortic ruptured plaques assessed by non-obstructive general angioscopy
Doctor K. Kojima (Tokyo, JP)
Abstract
Presentation thumbnail
Inflammation promotes extra-adrenal-ang II–independent aldosterone release by circulating immune cells in patients with coronary artery disease
Doctor A. Mroueh (Strasbourg, FR)
Abstract
Presentation thumbnail
SGLT2 inhibitor dapagliflozin attenuates cardiomyocyte injury and inflammation induced by PI3Kα-selective inhibitor alpelisib and fulvestrant under hyperglycemia
Doctor V. Quagliariello (Naples, IT)
Abstract
Presentation thumbnail
Impact of inclisiran on the cardiometabolic–inflammatory index: a real-world observational study
Doctor Q. Zhang (Guangzhou, CN)
Abstract

Access the full session

Session thumbnail
Targeting inflammation in cardiovascular diseases and pre-clinical models

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of colchicine on major limb and cardiovascular adverse events in peripheral artery disease: a pilot meta-analysis
15 March 2025
thumbnail
Congress Presentation
Comparative effectiveness of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a comprehensive Bayesian network meta-analysis with intervention ranking
1 September 2025
thumbnail
Congress Presentation
Optimizing antiplatelet therapy in ACS: a network meta-analysis of simplified regimens
1 September 2025
thumbnail
Congress Presentation
Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources